May 20, 2020 / 6:23 AM / 6 days ago

AstraZeneca-Merck's Lynparza gets U.S. FDA nod for prostate cancer

May 20 (Reuters) - The U.S. Food and Drug Administration approved AstraZeneca Plc and Merck & Co Inc's Lynparza as a treatment for a form of prostate cancer, the companies said in a joint statement on Wednesday.

The drug approval is for patients with a form of gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Reporting by Aakash Jagadeesh Babu in Bengaluru; editing by Uttaresh.V)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below